Home > Academic Announcements > (Nov. 1) Frontiers in Medical Sciences Lecture 308: Phage - mammalian cell double display screening high expression of high affinity full-length human monoclonal antibodies

(Nov. 1) Frontiers in Medical Sciences Lecture 308: Phage - mammalian cell double display screening high expression of high affinity full-length human monoclonal antibodies

Last updated :2017-10-31

Topic: Phage - mammalian cell double display screening high expression of high affinity full-length human monoclonal antibodies
Speaker: Professor Chen Zhou
Host:
Professor Guangmei Yan (Zhongshan School of Medicine, SYSU)
Time: 10:30 am, Wednesday, November 1, 2017
Venue: Room 946, 9th Floor, Science and Technology Building, Guangzhou North Campus, SYSU

About the speaker:
Dr Zhou Chen is the general manager of Shanghai sword biotechnology co., ltd. He is focusing on the screening of full-length human monoclonal antibodies and the development of new antibody drugs.

Dr Zhou Chen is graduated from the military medical department of the first military medical university of Guangzhou, and received a master and doctor degree from the fourth military medical university of Xi' an, and a postdoctoral and visiting scholar at the university of southern California in 1987. In 1996, he entered and became a researcher at immusol company in San Diego, California, USA, and Amgen (Amgen), the world bio - pharmaceutical company. He served as deputy general manager and chief scientist in many biotechnology companies in China.He also served as visiting professor / distinguished professor in southern medical university ( former first military medical university ) of southern medical university. He published more than 20 papers in the journals of jbc, blood, mabs, abbs, and PLoS one.

For more than ten years, he worked on the research and development of antibody display technology for mammalian cell surface, the construction of full-length human antibody library, the humanized modification of antibody, the establishment of high expression of high affinity antibody screening and the establishment of screening platform. The research and development of full - length antibody display technology for mammalian cell surface and double display monoclonal antibody screening technology are the leading international and domestic only.